| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hideki Miura, Tomitsune Kitagami, Norio Ozak. Suppressive effect of paroxetine, a selective serotonin uptake inhibitor, on tetrahydrobiopterin levels and dopamine as well as serotonin turnover in the mesoprefrontal system of mice. Synapse (New York, N.Y.). vol 61. issue 9. 2007-11-29. PMID:17559097. |
suppressive effect of paroxetine, a selective serotonin uptake inhibitor, on tetrahydrobiopterin levels and dopamine as well as serotonin turnover in the mesoprefrontal system of mice. |
2007-11-29 |
2023-08-12 |
mouse |
| Hideki Miura, Tomitsune Kitagami, Norio Ozak. Suppressive effect of paroxetine, a selective serotonin uptake inhibitor, on tetrahydrobiopterin levels and dopamine as well as serotonin turnover in the mesoprefrontal system of mice. Synapse (New York, N.Y.). vol 61. issue 9. 2007-11-29. PMID:17559097. |
in the present study, we investigated the effect of paroxetine, a selective serotonin reuptake inhibitor (ssri), on the bh(4) levels and dopamine (da) and serotonin (5-ht) turnover in the mesoprefrontal system, incorporating two risk factors of depression, social isolation and acute environmental change. |
2007-11-29 |
2023-08-12 |
mouse |
| Hideki Miura, Tomitsune Kitagami, Norio Ozak. Suppressive effect of paroxetine, a selective serotonin uptake inhibitor, on tetrahydrobiopterin levels and dopamine as well as serotonin turnover in the mesoprefrontal system of mice. Synapse (New York, N.Y.). vol 61. issue 9. 2007-11-29. PMID:17559097. |
thus, social isolation may have influenced the suppressive effects of paroxetine on bh(4) levels as well as exerted an influence on da and 5-ht turnover. |
2007-11-29 |
2023-08-12 |
mouse |
| Kathryn R Starr, Gary W Price, Jeannette M Watson, Peter J Atkinson, Roberto Arban, Sergio Melotto, Lee A Dawson, Jim J Hagan, Neil Upton, Mark S Duxo. SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 10. 2007-11-20. PMID:17356576. |
5-ht uptake was inhibited by sb-649915-b at all time points to a similar magnitude as that seen with paroxetine. |
2007-11-20 |
2023-08-12 |
human |
| Christian Schuster, Nora Fernbach, Uwe Rix, Giulio Superti-Furga, Marion Holy, Michael Freissmuth, Harald H Sitte, Veronika Sex. Selective serotonin reuptake inhibitors--a new modality for the treatment of lymphoma/leukaemia? Biochemical pharmacology. vol 74. issue 9. 2007-11-19. PMID:17709099. |
the structure-activity relationship readily distinguished the pro-apoptotic and growth inhibitory effect of ssris from their eponymous action (blockage of the serotonin transporter): acetylation of the ssris fluvoxamine and paroxetine abrogated the ability of these compounds to inhibit 5ht-uptake, but did not impair their cytotoxic action. |
2007-11-19 |
2023-08-12 |
Not clear |
| Guang Qiu, Daiga M Helmeste, Asanka N Samaranayake, Wui-Man Lau, Tatia M C Lee, Siu-Wa Tang, Kwok-Fai S. Modulation of the suppressive effect of corticosterone on adult rat hippocampal cell proliferation by paroxetine. Neuroscience bulletin. vol 23. issue 3. 2007-09-26. PMID:17612590. |
paroxetine, a selective serotonin reuptake transporter, is a commonly used antidepressant for alleviation of signs and symptoms of clinical depression. |
2007-09-26 |
2023-08-12 |
rat |
| Nadège Castaing, Karine Titier, Mathilde Receveur-Daurel, Maité Le-Déodic, Delphine Le-bars, Nicholas Moore, Mathieu Molimar. Quantification of eight new antidepressants and five of their active metabolites in whole blood by high-performance liquid chromatography-tandem mass spectrometry. Journal of analytical toxicology. vol 31. issue 6. 2007-09-26. PMID:17725879. |
a liquid chromatography-tandem mass spectrometry method is described for the blood determination of selective serotonin reuptake inhibitors (fluoxetine, paroxetine, sertraline, fluvoxamine, and citalopram), serotonin noradrenaline reuptake inhibitors (milnacipram and venlafaxine), a noradrenergic and specific serotoninergic antidepressant (mirtazapine) and five of their active metabolites (norfluoxetine, desmethylcitalopram, didesmethylcitalopram, desmethylvenlafaxine, and desmethylmirtazapine). |
2007-09-26 |
2023-08-12 |
Not clear |
| Benjamin Bar-Oz, Thomas Einarson, Adrienne Einarson, Radinka Boskovic, Lisa O'Brien, Heli Malm, Anick Bérard, Gideon Kore. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clinical therapeutics. vol 29. issue 5. 2007-09-05. PMID:17697910. |
recent studies suggest that paroxetine, a selective serotonin reuptake inhibitor (ssri), might specifically increase teratogenic risk. |
2007-09-05 |
2023-08-12 |
Not clear |
| Jennifer K Carroll, Sadhna Kohli, Karen M Mustian, Joseph A Roscoe, Gary R Morro. Pharmacologic treatment of cancer-related fatigue. The oncologist. vol 12 Suppl 1. 2007-08-23. PMID:17573455. |
other therapeutic agents that are less well studied for crf but are currently the focus of clinical trials include l-carnitine, modafinil, bupropion, and selective serotonin reuptake inhibitors such as paroxetine. |
2007-08-23 |
2023-08-12 |
Not clear |
| John Patrick Welsh, Carrie Ann Cusack, Christine K. Urticarial vasculitis secondary to paroxetine. Journal of drugs in dermatology : JDD. vol 5. issue 10. 2007-08-13. PMID:17373154. |
paroxetine (paxil) is a widely prescribed antidepressant of the selective serotonin reuptake inhibitor (ssri) class for which multiple cutaneous adverse effects have been reported, including urticaria, ecchymoses, vasculitis, and pruritus. |
2007-08-13 |
2023-08-12 |
Not clear |
| N R Mirza, E Ø Nielsen, K B Troelse. Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Progress in neuro-psychopharmacology & biological psychiatry. vol 31. issue 4. 2007-08-03. PMID:17335951. |
to determine the reproducibility of these effects and their generality to other antidepressants we compared the effects of chronic duloxetine treatment with another snri, venlafaxine, and two selective serotonin reuptake inhibitors, paroxetine and fluoxetine. |
2007-08-03 |
2023-08-12 |
mouse |
| Nobuaki Egashira, Satoko Harada, Ryoko Okuno, Michihiko Matsushita, Ryoji Nishimura, Kenichi Mishima, Katsunori Iwasaki, Kensuke Orito, Michihiro Fujiwar. Involvement of the sigma1 receptor in inhibiting activity of fluvoxamine on marble-burying behavior: comparison with paroxetine. European journal of pharmacology. vol 563. issue 1-3. 2007-08-03. PMID:17349995. |
in the present study, we examined the involvement of the sigma1 receptor in the inhibitory effect of the selective serotonin reuptake inhibitor (ssri) fluvoxamine, compared with that of paroxetine, on marble-burying behavior, which is an animal model of obsessive-compulsive disorder. |
2007-08-03 |
2023-08-12 |
Not clear |
| Per Plenge, Ulrik Gether, Søren G Rasmusse. Allosteric effects of R- and S-citalopram on the human 5-HT transporter: evidence for distinct high- and low-affinity binding sites. European journal of pharmacology. vol 567. issue 1-2. 2007-07-27. PMID:17499240. |
the hsert mutations did not alter affinities for 5-ht or paroxetine, but high-affinity binding of s-citalopram was severely affected, particularly by the i172m, and y95f/i172m mutations - k(i) respectively 4 nm (wild-type), 35 nm, 1000 nm, and 17.100 nm (mutants). |
2007-07-27 |
2023-08-12 |
human |
| Koji Shinkai, Yumiko Toyohira, Reiji Yoshimura, Masato Tsutsui, Susume Ueno, Jun Nakamura, Nobuyuki Yanagihar. Stimulation of catecholamine synthesis via activation of p44/42 MAPK in cultured bovine adrenal medullary cells by milnacipran. Naunyn-Schmiedeberg's archives of pharmacology. vol 375. issue 1. 2007-07-05. PMID:17211600. |
incubation of adrenal medullary cells with milnacipran (300 ng/ml, 1,065 nm) for 20 min resulted in a significant increase in 14c-catecholamine synthesis from [14c]tyrosine, but not from [14c]dopa, whereas the selective serotonin reuptake inhibitors (ssris), paroxetine (300 ng/ml, 800 nm) and fluvoxamine (300 ng/ml, 691 nm), had little effect. |
2007-07-05 |
2023-08-12 |
cattle |
| Demian Halperin, Guido Rebe. Influence of antidepressants on hemostasis. Dialogues in clinical neuroscience. vol 9. issue 1. 2007-06-26. PMID:17506225. |
drugs with the highest degree of serotonin reuptake inhibition--fluoxetine, paroxetine, and sertraline--are more frequently associated with abnormal bleeding and modifications of hemostasis markers. |
2007-06-26 |
2023-08-12 |
Not clear |
| Alexander Panickacheril John, Radhakrishan Kolot. Severe serotonin toxicity and manic switch induced by combined use of tramadol and paroxetine. The Australian and New Zealand journal of psychiatry. vol 41. issue 2. 2007-06-14. PMID:17484083. |
severe serotonin toxicity and manic switch induced by combined use of tramadol and paroxetine. |
2007-06-14 |
2023-08-12 |
Not clear |
| Roberto Mandrioli, Laura Mercolini, Anna Ferranti, Sandra Furlanetto, Giancarlo Boncompagni, Maria Augusta Ragg. Determination of the antidepressant paroxetine and its three main metabolites in human plasma by liquid chromatography with fluorescence detection. Analytica chimica acta. vol 591. issue 2. 2007-06-01. PMID:17481400. |
a high-performance liquid chromatographic method has been developed for the determination in human plasma of the specific serotonin reuptake inhibitor (ssri) antidepressant paroxetine and its three main metabolites (m1, m2, m3). |
2007-06-01 |
2023-08-12 |
human |
| Jonathan R T Davidso. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? The Journal of clinical psychiatry. vol 67 Suppl 12. 2007-05-30. PMID:17092192. |
the selective serotonin reuptake inhibitors (ssris) paroxetine, sertraline, fluoxetine, fluvoxamine, and escitalopram and the serotonin-norepinephrine reuptake inhibitor venlafaxine are effective treatments. |
2007-05-30 |
2023-08-12 |
Not clear |
| Shannon K Robinson, Erik S Viirre, Murray B Stei. Antidepressant therapy in tinnitus. Hearing research. vol 226. issue 1-2. 2007-05-22. PMID:16973315. |
survey the literature on antidepressants and tinnitus including tinnitus reported as a side effect of antidepressants (phenelzine, amitriptyline, protriptyline, doxepin, imipramine, fluoxetine, trazadone, bupropion, venlafaxine), tinnitus associated with withdrawal of antidepressants (venlafaxine and sertraline) and antidepressants as a treatment for tinnitus (case reports--fluoxetine and paroxetine, retrospective reviews--imipramine and selective serotonin reuptake inhibitors, single blind trials of amitriptyline and double blind placebo controlled trials of trimipramine, nortriptyline, paroxetine and sertraline). |
2007-05-22 |
2023-08-12 |
Not clear |
| Stephen S Gottlieb, Willem J Kop, Sue A Thomas, Scott Katzen, Mark R Vesely, Nancy Greenberg, Joanne Marshall, Michelle Cines, Stacey Minshal. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. American heart journal. vol 153. issue 5. 2007-05-22. PMID:17452166. |
because the response to depression treatment has not been evaluated in this patient population, we evaluated the efficacy of controlled-release paroxetine (paroxetine cr), a selective serotonin reuptake inhibitor, on depression and quality of life in chronic heart failure. |
2007-05-22 |
2023-08-12 |
Not clear |